SEATTLE, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (Nasdaq:CASC), a clinical-stage biopharmaceutical company, today announced that it has been selected for addition to the Nasdaq Biotechnology Index® (Nasdaq:NBI), which will become effective prior to U.S. market open on Monday, December 18, 2017.
The Nasdaq Biotechnology Index is designed to track the performance of a set of securities listed on the Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The Nasdaq Biotechnology Index is re-ranked annually and all securities in the index are listed on the Nasdaq Global Market or the Nasdaq Global Select Market, and meet minimum market value and share volume requirements among other criteria. For more information about the Nasdaq Biotechnology Index, including eligibility criteria, visit www.nasdaq.com.
About Cascadian Therapeutics
Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. Its lead product candidate, tucatinib, is an investigational oral, selective small molecule HER2 inhibitor. Cascadian Therapeutics is conducting a randomized, double-blind, controlled pivotal clinical trial called HER2CLIMB, which is comparing tucatinib vs. placebo, each in combination with capecitabine and trastuzumab, in patients with locally advanced or metastatic HER2+ breast cancer with and without brain metastases, who have previously been treated with trastuzumab, pertuzumab and T-DM1. Additional details on HER2CLIMB can be found at www.HER2CLIMB.com or www.clinicaltrials.gov. Tucatinib is also being studied in other cancers through investigator initiated studies, including HER2+ metastatic colorectal cancer and earlier lines of HR+/HER2+ metastatic breast cancer. For more information, please visit www.cascadianrx.com.
Source: Cascadian Therapeutics, Inc.
Source:Cascadian Therapeutics, Inc.